Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ WARS2 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5100806
Description
Antibody detects endogenous levels of total TrpRS.
Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in tRNAs, aminoacyl-tRNA synthetases are thought to be among the first proteins that appeared in evolution. Two forms of tryptophanyl-tRNA synthetase exist, a cytoplasmic form, named WARS, and a mitochondrial form, named WARS2. This gene encodes the mitochondrial tryptophanyl-tRNA synthetase. Two alternative transcripts encoding different isoforms have been described.
Specifications
WARS2 | |
Polyclonal | |
Unconjugated | |
WARS2 | |
(Mt)TrpRS; 5730427B17Rik; 9430020O07Rik; AI413375; mitochondrial rryptophanyl-tRNA synthetase-like protein; mitochondrial tryptophanyl-tRNA synthetase 2; trpRS; tryptophan tRNA ligase 2, mitochondrial; tryptophan--tRNA ligase, mitochondrial; tryptophanyl tRNA synthetase 2 (mitochondrial); tryptophanyl tRNA synthetase 2, mitochondrial; Tryptophanyl-tRNA synthetase; tryptophanyl-tRNA synthetase, mitochondrial; tryptophanyl-tRNA synthetase, mitochondrial; tryptophan--tRNA ligase, mitochondrial; WARS2; zgc:110828 | |
Rabbit | |
Affinity chromatography | |
RUO | |
10352, 70560 | |
-20°C | |
Liquid |
Western Blot | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
Q9CYK1, Q9UGM6 | |
WARS2 | |
A synthesized peptide derived from human WARS2(Accession Q9UGM6), corresponding to amino acid residues K199-Q249. | |
100 μL | |
Primary | |
Human, Mouse | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction